AzTrials
AzTrials

BioavailabilityNCT05840848

Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males

A study of Bioavailability, run by University of Hohenheim at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial. Read more about this study

Who is it for?
Ages 18 to 50 years, men onlyHealthy volunteers can take part
Conditions the study is for
Bioavailability
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
12 participants
Where
1 siteGermany
Study dates
21 Nov 2017to 1 Jun 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male
  • aged 18 and 50 years

Who cannot join

  • overweight (BMI >25 kg/m2),
  • metabolic and endocrine diseases,
  • drug abuse,
  • use of dietary supplements,
  • us of any form of medication,
  • smoking,
Show all 11Show fewer
  • frequent alcohol consumption (>20 g ethanol/day),
  • adherence to a restrictive dietary regimen,
  • physical activity of more than 5 h/wk,
  • participation in a clinical trial within the past 3 months prior to recruitment,
  • a known intolerance against β-carotene, iron and/or zinc supplements.

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • University of Hohenheim

    Stuttgart, Baden-Wurttemberg, 70599

Other trials in Germany

About this study

Official title: Effect of Simultaneously Consuming Iron and Zinc Supplements With That of B-carotene, on the B-carotene Bioavailability in Healthy Males

In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial.

Healthy males (n=6) ingested, with breakfast, a single dose of 15 mg β-carotene in combination with either a placebo, 25 mg iron or 30 mg zinc capsule. Blood samples were collected at baseline and hourly for 10 hours. The triacylglycerol-rich fraction (TRF) was analysed for concentrations of β-carotene and plasma for β-carotene, retinol, triacylglycerols, LDL- and HDL-cholesterol.

Read the detailed description

The study followed a double-blind crossover design with three study arms separated by one week washout periods. In short, the participants were asked to follow a diet low in carotenoids by avoiding all orange, yellow, red and green fruits and vegetables for four days. This was followed by three days of a strictly carotenoid-free diet, which only allowed foods from a specified list (Supplemental Table A2). On each study day, β-carotene was administered in the morning after a >10 hour overnight fast (Supplemental Figure A1). All participants orally ingested, in random order, a single dose of 15 mg β-carotene (BIOVEA) with either a placebo (empty capsule), 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany) or 30 mg zinc (ZnSO4; Woerwag Pharma) capsule. A standardised dinner was provided on the evening before the trial and standardised meals were provided during the entire intervention day (Supplemental Table A3). On the first study day, the amount of food (weight or volume) consumed by each participant for each meal was recorded and the same amounts provided during the following two arms to ensure similar food consumption, especially of fat. Water was available unrestricted for consumption throughout the day. Blood samples were drawn from an indwelling venous cannula and collected at 0 hours directly before β-carotene supplementation and then every hour for 10 hours.

For the determination of plasma concentrations of β-carotene, LDL- and HDL-cholesterol, and triacylglycerols (TAG), blood was collected in tubes containing EDTA (Sarstedt AG \& Co, Nuebrecht, Germany) and immediately centrifuged (3000 × g, 10 min, 4 °C). From the obtained plasma samples, three aliquots were stored at -80 °C until further analysis and the rest ultracentrifuged to obtain the triacylglycerol-rich fraction (TRF). For the analyses of liver and kidney function markers, plasma and serum were obtained from blood sampled at the 0- and 4-hour time points.

The TRF was prepared according to [10]. Briefly, plasma (3.5 mL) was transferred to an ultracentrifuge tube and carefully overlaid with 8 mL 1.3% sodium chloride and then ultracentrifuged (Beckman Coulter, OptimaTM L-80 XP Ultracentrifuge) using a swinging bucket rotor (SW41Ti) at 150 000 x g for 1 hour at 4 °C. Afterwards, the TRF was isolated by transferring the upper ~6 mL, which was then overlaid with nitrogen gas to minimize oxidation and stored at -80 °C until extraction.

The plasma samples were randomly extracted and analysed by HPLC according to [15]. Briefly, 40 µL plasma was extracted with an ethanol/n-butanol mixture (50:50) containing apo-80-carotenal-methyloxime (12µL/100 mL; Fluka Analytical (Merck Group KGaA), Darmstadt, Germany) as internal standard. After centrifugation, the clear supernatant was analysed by HPLC.

The TRF was extracted and analysed by HPLC [15]. For the extraction, 100 µl apo-80-carotenal-methyloxime (12 µL/100 mL) and 2 mL ethanol (for deproteination) were added to 3 mL of the TRF and vortexed for 30 sec. The solution was extracted twice with 2 mL hexane. The hexane layers were removed, combined and evaporated in a centrifugal vacuum concentrator (Christ, RVC 2-25 CD plus) and the dried sample re-dissolved in 100 µL acetonitrile and immediately analysed by HPLC.

Both the plasma and TRF samples were analysed using a Shimadzu HPLC (LC-10AD) equipped with a UV-Vis detector (SPD 20A, set at 450 nm). Carotenoids were separated using a ReproSil 80 ODS-2 column (3 µm, 250 x 4.6 mm; Dr. Maisch GmbH, Ammerbuch, Germany) and an eluent in recirculation mode (82% acetonitrile, 15% 1,4-dioxin, and 3% methanol (vol/vol) containing 100 mM ammonium acetate and 10 mM triethylamine) at a flow rate of 1.5 mL/min [15]. A β-carotene standard (≥97.0% purity, Sigma-Aldrich) was used to construct a standard curve.

Plasma TAG, HDL- and LDL-cholesterol were analysed by a clinical laboratory (Laborärzte Sindelfingen, Sindelfingen, Germany).

Conditions
Bioavailability
Being tested
Control beta-carotene supplement plus Placebo, Control beta-carotene supplement plus iron Supplement, Control beta-carotene supplement plus zinc Supplement
Keywords
B-carotene, Iron, zinc, Supplements

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Control beta-carotene supplement plus PlaceboDietary supplement

    15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.

  • Control beta-carotene supplement plus iron SupplementDietary supplement

    15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)

  • Control beta-carotene supplement plus zinc SupplementDietary supplement

    15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)

Study groups in NCT05840848
Study groupRoleWhat they receive
Control plus PlaceboActive comparatorB-carotene supplement (15 mg) consumed in the morning after a >10 hour overnight fast.
Receives: Dietary Supplement: Control beta-carotene supplement plus Placebo
Control plus iron SupplementExperimentalB-carotene supplement (15 mg) and iron sulphate supplement (25 mg) consumed in the morning after a >10 hour overnight fast.
Receives: Dietary Supplement: Control beta-carotene supplement plus iron Supplement
Control plus zinc SupplementExperimentalB-carotene supplement (15 mg) and zinc sulphate supplement (30 mg) consumed in the morning after a >10 hour overnight fast.
Receives: Dietary Supplement: Control beta-carotene supplement plus zinc Supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. TRF B-carotene

    B-carotene concentration in the triacylglycerol-rich fraction of the plasma

    Measured: 10 hours

  2. Plasma B-carotene

    B-carotene concentration int he plasma

    Measured: 10 hours

Secondary outcomes (5)
  1. Plasma LDL-cholesterol

    LDL-cholesterol concentration in Plasma

    Measured: 10 hours

  2. Plasma HDL-cholesterol

    HDL-cholesterol concentration in Plasma

    Measured: 10 hours

  3. Plasma TAG

    triacylglycerol concentration in Plasma

    Measured: 10 hours

  4. liver function markers

    γ-GT, AST, ALT, Alkaline phosphatase and Bilirubin measured

    Measured: 4 hours

  5. Kidney funtion markers

    Creatinine i.S. and Uric acid measured

    Measured: 4 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 May 2023
  2. Study start21 Nov 2017
  3. Primary completion14 Dec 2017
  4. Study completion1 Jun 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Crossover
Model description
double-blind crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05840848
Sponsor's protocol ID
AZ: F-2017-039
Status last verified
May 2023
First submitted
28 Mar 2023
Last updated
6 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Kruger J, Sus N, Moser A, Scholz S, Adler G, Venturelli S, Frank J. Low beta-carotene bioaccessibility and bioavailability from high fat, dairy-based meal. Eur J Nutr. 2024 Sep;63(6):2261-2270. doi: 10.1007/s00394-024-03423-w. Epub 2024 May 16.

    PubMed 38753174

Questions about this trial

What is this clinical trial studying?

A study of Bioavailability, run by University of Hohenheim at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

TRF B-carotene (time frame: 10 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05840848, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in